Suppr超能文献

表征聚乙二醇对表面蛋白的修饰以阻断血小板黏附。

Characterizing the modification of surface proteins with poly(ethylene glycol) to interrupt platelet adhesion.

作者信息

Xu Haiyan, Kaar Joel L, Russell Alan J, Wagner William R

机构信息

Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China.

出版信息

Biomaterials. 2006 Jun;27(16):3125-35. doi: 10.1016/j.biomaterials.2006.01.012. Epub 2006 Feb 2.

Abstract

Surface protein modification with poly(ethylene glycol) (PEG) can inhibit acute thrombosis on damaged vascular and biomaterial surfaces by blocking surface protein-platelet interactions. However, the feasibility of employing protein reactive PEGs to limit intravascular and biomaterial thrombosis in vivo is contingent upon rapid and extensive surface protein modification. To characterize the factors controlling this potential therapeutic approach, the model protein bovine serum albumin was adsorbed onto polyurethane surfaces and modified with PEG-carboxymethyl succinimidyl ester (PEG-NHS), PEG-isocyanate (PEG-ISO), or PEG-diisocyanate (PEG-DISO) in aqueous buffer at varying concentrations and contact times. It was found that up to 5 PEGs could be attached per albumin molecule within one min and that adsorbed albumin PEGylation approached maximal levels by 6min. The lability of reactive PEGs in aqueous buffer reduced total protein modification by 50% when the PEG solution was incubated for 7min prior to application. For fibrinogen PEGylation (performed in the solution phase), PEG-NHS was more reactive than PEG-ISO or PEG-DISO. The gamma peptide of fibrinogen, which contains several key platelet-binding motifs, was highly modified. A marked reduction in platelet adhesion was observed on fibrinogen-adsorbed polyurethane treated with PEG-NHS or PEG-DISO. Relative differences in platelet adhesion on PEG-NHS and PEG-DISO modified surfaces could be attributed to differences in reactivity towards fibrinogen and the size of the polymer backbone. Taken together, these findings provide insight and guidance for applying protein reactive PEGs for the interruption of acute thrombotic deposition.

摘要

用聚乙二醇(PEG)对表面蛋白进行修饰可通过阻断表面蛋白与血小板的相互作用来抑制受损血管和生物材料表面的急性血栓形成。然而,在体内使用蛋白反应性PEGs来限制血管内和生物材料血栓形成的可行性取决于快速且广泛的表面蛋白修饰。为了表征控制这种潜在治疗方法的因素,将模型蛋白牛血清白蛋白吸附到聚氨酯表面,并在不同浓度和接触时间下,于水性缓冲液中用PEG-羧甲基琥珀酰亚胺酯(PEG-NHS)、PEG-异氰酸酯(PEG-ISO)或PEG-二异氰酸酯(PEG-DISO)进行修饰。结果发现,每个白蛋白分子在1分钟内最多可连接5个PEG,且吸附的白蛋白聚乙二醇化在6分钟时接近最大水平。当PEG溶液在应用前孵育7分钟时,反应性PEGs在水性缓冲液中的不稳定性使总蛋白修饰减少了50%。对于纤维蛋白原的聚乙二醇化(在溶液相中进行),PEG-NHS比PEG-ISO或PEG-DISO更具反应性。纤维蛋白原的γ肽含有几个关键的血小板结合基序,被高度修饰。在用PEG-NHS或PEG-DISO处理的吸附有纤维蛋白原的聚氨酯上,观察到血小板粘附显著减少。PEG-NHS和PEG-DISO修饰表面上血小板粘附的相对差异可归因于对纤维蛋白原的反应性差异和聚合物主链的大小。综上所述,这些发现为应用蛋白反应性PEGs中断急性血栓沉积提供了见解和指导。

相似文献

1
Characterizing the modification of surface proteins with poly(ethylene glycol) to interrupt platelet adhesion.
Biomaterials. 2006 Jun;27(16):3125-35. doi: 10.1016/j.biomaterials.2006.01.012. Epub 2006 Feb 2.
5
Molecular barriers to biomaterial thrombosis by modification of surface proteins with polyethylene glycol.
Biomaterials. 1998 Oct;19(20):1885-93. doi: 10.1016/s0142-9612(98)00098-2.
6
Molecular barriers to biomaterial thrombosis by modification of surface proteins with polyethylene glycol.
Biomaterials. 1999 Jan;20(2):101-9. doi: 10.1016/s0142-9612(98)00001-5.
8
Polyethylene glycol diisocyanate decreases platelet deposition after balloon injury of rabbit femoral arteries.
J Thromb Thrombolysis. 2002 Feb;13(1):27-33. doi: 10.1023/a:1015364024487.
9
Poly(ethylene glycol) grafting to poly(ether imide) membranes: influence on protein adsorption and thrombocyte adhesion.
Macromol Biosci. 2013 Dec;13(12):1720-9. doi: 10.1002/mabi.201300309. Epub 2013 Oct 29.
10
Chondroitin sulfate coatings display low platelet but high endothelial cell adhesive properties favorable for vascular implants.
Biomacromolecules. 2014 Jul 14;15(7):2512-20. doi: 10.1021/bm5003762. Epub 2014 Jun 25.

引用本文的文献

1
Tailored Branched Polymer-Protein Bioconjugates for Tunable Sieving Performance.
ACS Macro Lett. 2024 Apr 16;13(4):461-467. doi: 10.1021/acsmacrolett.4c00059. Epub 2024 Apr 4.
2
Moving Protein PEGylation from an Art to a Data Science.
Bioconjug Chem. 2022 Sep 21;33(9):1643-1653. doi: 10.1021/acs.bioconjchem.2c00262. Epub 2022 Aug 22.
3
The Effect of Covalently-Attached ATRP-Synthesized Polymers on Membrane Stability and Cytoprotection in Human Erythrocytes.
PLoS One. 2016 Jun 22;11(6):e0157641. doi: 10.1371/journal.pone.0157641. eCollection 2016.
4
In vivo PEG modification of vascular surfaces for targeted delivery.
J Vasc Surg. 2012 Apr;55(4):1087-95. doi: 10.1016/j.jvs.2011.09.081. Epub 2011 Dec 9.
5
Injectable thermosensitive hydrogel based on chitosan and quaternized chitosan and the biomedical properties.
J Mater Sci Mater Med. 2009 Aug;20(8):1603-10. doi: 10.1007/s10856-009-3729-x. Epub 2009 Mar 26.
6
Targeting microspheres and cells to polyethylene glycol-modified biological surfaces.
J Biomed Mater Res A. 2007 Jun 1;81(3):578-85. doi: 10.1002/jbm.a.31092.

本文引用的文献

5
Progress in the field of GPIIb/IIIa antagonists.
Curr Med Chem Cardiovasc Hematol Agents. 2004 Apr;2(2):157-67. doi: 10.2174/1568016043477224.
6
Pathophysiologic roles of the fibrinogen gamma chain.
Curr Opin Hematol. 2004 May;11(3):151-5. doi: 10.1097/01.moh.0000131440.02397.a4.
7
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates.
Adv Drug Deliv Rev. 2003 Sep 26;55(10):1261-77. doi: 10.1016/s0169-409x(03)00108-x.
9
Synthesis of polyethylene glycol (PEG) derivatives and PEGylated-peptide biopolymer conjugates.
Biomacromolecules. 2003 Jul-Aug;4(4):1055-67. doi: 10.1021/bm034069l.
10
Modification of clearance of therapeutic and potentially therapeutic proteins.
Curr Drug Targets Cardiovasc Haematol Disord. 2001 Jun;1(1):1-22. doi: 10.2174/1568006013338150.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验